The renin-angiotensin system medicine sales in Italy stood at 1.14 billion euros in 2023. Forecast for the years 2024 through 2028 indicates stability with a minor decline beginning in 2027, dropping to 1.13 billion euros in 2027 and 2028. The year-on-year variation from 2027 to 2028 is approximately -0.88%, representing a slight contraction. The 5-year compound annual growth rate (CAGR) suggests minimal change owing to consistent figures over the years.

Future trends to watch for include:

Advances in alternative hypertension treatment methodologies which could impact these forecasts.
Regulatory shifts and healthcare policy changes in Italy that might encourage the adoption of new pharmaceutical products.
The potential impact of economic conditions on healthcare spending and drug pricing structures.